Introduction {#s1}
============

Human cancers share common features of genome instability and mutagenesis ([@bib32]) that are the sources of the 10^3^ to 10^6^ somatic mutations observed in the genomes of most types of adult tumors ([@bib90]; [@bib97]). The total mutation burden in a tumor is the result of multiple mutational pathways operating within the cells at varying rates over time. This can complicate attempts to assign the relative contributions of each pathway to the mutation spectrum of a tumor. One essential tool to our understanding of how mutations accumulate and influence tumor progression is using computational means to extract multiple individual signatures from many tumor genomes ([@bib5]; [@bib7]; [@bib33]). This is proving to be instrumental in resolving the relative extents to which pathways contribute to the ultimate mutation spectrum in a tumor ([@bib71]; [@bib80]). Comparing these tumor mutation signatures to those generated in experimental cell lines is another critical tool to understanding the relative rates and causality of mutation acquisition ([@bib25]; [@bib36]). Traditionally, these measurements have relied on assays using reporter genes, which necessarily look at a tiny fraction of the genome and may miss global contributions to genome instability. Advances in next generation sequencing now allow for detailed genome-wide analyses of mutation accumulation over defined periods of cellular growth. Since each nucleotide in the genome is subject to the three major determinants of replication fidelity - nucleotide selection, proofreading and mismatch repair (MMR) - during every round of replication, tumors and cells with defects in replication fidelity are uniquely poised to address these issues.

Proofreading defects are now known to occur in a wide variety of tumors, with significant enrichment in colorectal and endometrial tumors ([@bib16]; [@bib46]; [@bib35]; [@bib79]). Mutations in DNA polymerase (Pol) ε cluster in the exonuclease proofreading domain and the tumors are clinically characterized by several criteria, including being ultrahypermutated, having a unique mutation spectrum, containing a heterozygous Pol ε mutation with no evidence of loss of heterozygosity (LOH) and being microsatellite stable (MSS) ([@bib14]; [@bib18]; [@bib73]; [@bib102]; [@bib37]; [@bib87]; [@bib88]; [@bib9]). Whole genome and whole exome analyses of tumors have been the primary means to establish the ultrahypermutated (\>100 Mutations per megabase) unique mutational signature that distinguish Pol ε tumors from other cancers ([@bib5]; [@bib7]; [@bib87]; [@bib88]; [@bib6]; [@bib15]). While there is a rich history of studies on the effects of exonuclease defects on mutagenesis in model organisms, the extent to which Pol ε proofreading-deficiency by itself drives each of these criteria remains poorly understood.

It is clear from studies in model organisms that complete, biallelic inactivation of Pol ε proofreading activity causes mutagenesis and carcinogenesis in model organisms, where mutation rates have been precisely measured using reporter genes. For example, mutation rates are increased in haploid or diploid yeast strains expressing only proofreading-deficient alleles of Pols ε ([@bib66]; [@bib68]; [@bib86]) or δ ([@bib67]; [@bib89]; [@bib38]). These rates are further elevated when combined with defects in mismatch repair, indicating that these errors are made during replication ([@bib68]; [@bib94]; [@bib93]; [@bib48]). In mouse models, homozygous inactivation of both copies of either Pol ε or δ exonuclease activity (Pol ε^exo-/exo-^ or Pol δ^exo-/exo-^) causes increased mutation rates and cancer ([@bib4]; [@bib30]; [@bib29]). Interestingly, their tumor spectra are different, with gastrointestinal tumors predominant in Pol ε^exo-/exo-^ mice while thymic lymphomas are the major tumor in Pol δ^exo-/exo-^ mice.

However, mice with a heterozygous inactivation of a single Pol ε proofreading allele (the monoallelic Pol ε^wt/exo-^ genotype) fail to develop tumors when mismatch repair is functional ([@bib4]). The equivalent diploid heterozygous Pol ε exonuclease mutant in yeast is also a mutator, but the effect is modest and partially dominant to the wild type allele and lacks the unique mutation spectrum seen in human tumors ([@bib68]; [@bib86]; [@bib67]; [@bib47]). These results raise critical questions as to the source of the unique, ultrahypermutant phenotype in human tumors with heterozygous Pol ε exonuclease-deficiency.

Mismatch repair is responsible for the recognition and removal of replication errors and deficiencies in this activity cause genome instabilities that can lead to cancer ([@bib50]; [@bib54]; [@bib45]; [@bib65]). Mismatch repair is normally an extremely efficient process, correcting more than 99% of replication errors. However, genome-wide studies have recently shown that MMR efficiencies can vary by over two orders of magnitude and are influenced by a number of factors, including the strand on which the mismatch occurs, the polymerase that made the error, the nature of the mismatch, local sequence context, distance from the origin and replication timing ([@bib34]; [@bib42]; [@bib59]; [@bib58]; [@bib91]). Patients with biallelic mismatch repair disorder (bMMRD) have biallelic germline inactivating mutations in a mismatch repair gene and are completely lacking mismatch repair and develop a number of early-onset tumors in which microsatellite instability (MSI) is readily detectable ([@bib23]; [@bib100]). A subset of these patients acquires a later somatic mutation in a single allele of Pol ε, leading to very aggressive tumor development. Mutation rates from these Pol ε^wt/exo-^ MMR^−/−^ tumors have been estimated on the order of several hundred per genome duplication ([@bib88]). This is consistent with results from model systems as mice with the equivalent genotype (heterozygous Pol ε^wt/exo-^ combined with homozygous MMR^−/−^) develop tumors within 1--2 months ([@bib95]). The equivalent yeast strains are strong mutators as well ([@bib86]; [@bib67]; [@bib48]).

However, since sporadic POLE tumors are generally microsatellite stable, the role of MMR in Pol ε proofreading-deficiency in the development of these MSS tumors remains a critical unanswered question. Whether MMR and POLE defects together are required for ultramutation, elevated mutation rates or for establishing the unique mutation signature is unknown. Understanding how MMR function or dysfunction affects proofreading-dependent mutagenesis is essential to understanding the mechanisms of mutagenesis during cancer development.

In the current study, we constructed a human cell line model system to address the roles of Pol ε proofreading in driving the clinical characteristics that define Pol ε tumors. Critically, we used a targeted knock-in approach to inactivate one copy of Pol ε 3\'−5\' exonuclease activity, since human tumors contain heterozygous, monoallelic Pol ε mutations. Using mutation rates measured at a reporter gene in combination with whole-exome and whole-genome sequencing we found a rapid accumulation of large numbers of Pol ε-specific mutations in mismatch repair-deficient cells. This confirms results suggested by observations in Pol ε mutant bMMRD tumors. We further show that mismatch repair is able to suppress exonuclease-deficient Pol ε-induced mutation rates back to wild type levels using a combination of reporter gene and whole-exome sequencing (WES). These results support the idea that additional unique features beyond a single exonuclease active site inactivation are helping facilitate the massive mutation acquisition seen in microsatellite stable tumors containing mutant Pol ε.

Results {#s2}
=======

Inactivation of Pol ε proofreading causes a mutator phenotype in human cells {#s2-1}
----------------------------------------------------------------------------

Tumors with mutations in the exonuclease domain of POLE are generally microsatellite stable and show no or low loss of heterozygosity, suggesting that inactivation of exonuclease activity in one allele is sufficient to drive mutagenesis and tumor development, though this has not been directly tested previously. To test whether inactivation of a single allele of Pol ε proofreading was sufficient to cause a mutator phenotype in human cells, we used recombinant adenoassociated virus (rAAV)-mediated gene targeting to engineer a diploid human cell line to express one allele of Pol ε with the D275A/E277A double substitution ([Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}--[2](#fig1s2){ref-type="fig"}; [Figure 1---source data 1](#fig1sdata1){ref-type="supplementary-material"}). We chose the D275A/E277A mutation because it inactivates exonuclease proofreading in vitro ([@bib86]; [@bib49]). The parental cell line, HCT-116, is constitutively mismatch repair-deficient due to an inactivating mutation in Mlh1, thus allowing us to first define the contributions of proofreading deficiency separately to mutagenesis. We then measured the mutation rate at the hypoxanthine-guanine phosphoribosyltransferase (HPRT1) locus using 6-thioguanine (6-TG) resistance and a fluctuation assay. The measurements were repeated in clones derived from independent exonuclease-deficient (exo-) allele integration events. A moderate mutator effect was seen in Pol ε^wt/exo-^ heterozygotes ([Figure 1A](#fig1){ref-type="fig"}), indicating the exo- allele was partially dominant over the endogenous exo + allele, similar to what is seen in a mismatch repair-deficient diploid cell line heterozygous for a Pol ε proofreading mutation, *pol2-4/+pms1/pms1* ([@bib76]). Mutation rates were not measured in cells from the comparable heterozygous Pol ε^wt/exo-^ mice lacking mismatch repair ([@bib4]).

![Heterozygous inactivation of Pol ε proofreading causes an increase in specific base pair substitutions.\
(**A**) Mutation rates were measured using the fluctuation assay at the HPRT1 locus by resistance to 6-thioguanine. Mutation rates and 95% confidence intervals were measured by fluctuation analysis as described in the Methods using the Ma-Sandri-Sarkar Maximum Likelihood Estimator. Twelve independent isolates of both the parental (wt/wt) cell line and two independently derived clones of the heterozygous cell lines (wt/exo-) were used. All cell lines were mismatch repair-deficient. P-values for Clones 1 and 2 (p=0.0017 and p=0.008, respectively) were calculated using an unpaired t-test relative to wt/wt. Mutation rates for Clone 1 and Clone 2 were not significantly different from one another (p=0.4727). (**B**) Error rates for base pair substitutions (BPS) and small insertion/deletion frameshift mutations (FS) were calculated using the mutation rate data from [Figure 1A](#fig1){ref-type="fig"}. Exo + BPS Error Rate = 27.6 × 10^−7^, SEM = 8.48 × 10^−7^, n = 12; Exo- BPS Error Rate = 178 × 10^−7^, SEM = 37.8 × 10^−7^, n = 8; p=0.0002. Exo + FS Error Rate = 18.4 × 10^−7^, SEM = 5.73 × 10^−7^, n = 8; Exo- FS Error Rate = 22.2 × 10^−7^, SEM = 12.1 × 10^−7^, n = 1; p=0.7759. Error rate data shown for Exo- is from Clone 1 (See [Figure 1A](#fig1){ref-type="fig"}). The HPRT1 ORF was sequenced from independently derived isolates of 6-TG resistant clones (these included 20 mismatch repair-deficient Pol ε^wt/wt^ and 25 mismatch repair-deficient Pol ε^wt/exo-^ clones; see Materials and methods). Sequence changes used to calculate error rates are in [Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}. \*\*\*p\<0.001; n.s., p\>0.05. (**C**) Errors rates were calculated using a lacZ reversion substrate that reverts via TCT→TAT transversion. P values were calculated using chi-square tests with Yates correction. Error rates are the averages of two experiments, each conducted with independent DNA and enzyme preparations for each construct tested. ≤indicates the value is a maximal estimate as it is identical to the assay background.\
10.7554/eLife.32692.006Figure 1---source data 1.Pol ε rAAV targeting efficiencies in human HCT-116 cells.HCT-116 cells (37.4 × 10^6^) were transduced with Pol ε rAAV and grown in the presence of 10 μg/ml G418 to select for Neo^r^ clones. Targeted clones were identified by PCR analysis.\
10.7554/eLife.32692.007Figure 1---source data 2.HPRT1 mutations sequenced from 6-thioguanine resistant Pol ε wt/exo- and Pol ε wt/wt HCT116 cells.For each cell line, HPRT1 cDNA was made by RT-PCR, amplified and sequenced from independent 6-thioguanine resistant clones. Verified errors are indicated by type on the coding strand and position relative to the +1 start site. Insertion (ins) or deletion (Δ) of the indicated base(s) is denoted.](elife-32692-fig1){#fig1}

To begin measuring the effect of inactivating a single Pol ε exonuclease allele on mutation rates in cells, we sequenced the HPRT1 gene from twenty and twenty-five independently derived 6-TG^R^ (and thus HPRT1 mutant) clones from mismatch repair-deficient Pol ε^wt/wt^ and Pol ε^wt/exo-^ cells, respectively ([Figure 1---source data 2](#fig1sdata2){ref-type="supplementary-material"}). This allowed comparison to previously measured mutation rates from different groups using the same parental cell line. Mutation rates from the Pol ε^wt/wt^ cells were similar to the spontaneous mutation rates reported by three previous studies ([@bib11]; [@bib28]; [@bib72]). These results suggest that the baseline rates of mutagenesis are an accurate measure of comparison for the Pol ε^wt/exo-^ cell lines.

The increase in mutation rate seen in the Pol ε^wt/exo-^ mismatch repair-deficient cells was primarily due to base pair substitutions ([Figure 1B](#fig1){ref-type="fig"}). Frameshift error rates did not change, in agreement with previous findings in vitro that Pol ε proofreading primarily strongly corrects base-base mispairs with little effect on frameshift fidelity ([@bib49]). However, the number of mutational events scored by this method is insufficient to make statistical claims regarding individual mutations, reinforcing the need for genome sequencing to examine mutations in all possible sequence contexts.

Using an in vitro lacZ reversion substrate that specifically measures TCT→TAT transversions ([@bib87]; [@bib88]), the D275A/E277A mutant made these errors at a significantly higher rate in vitro than the wild type exonuclease-proficient Pol ε enzyme ([Figure 1C](#fig1){ref-type="fig"}). We used a construct comprised of the N-terminal 140 kDa of Pol ε, which contains the DNA polymerase and exonuclease domains and has similar fidelity and catalytic activity to the complete four subunit holoenzyme ([@bib3]; [@bib27]; [@bib101]). Importantly, the elevated TCT→TAT error rate we observed with the D275A/E277A mutant was not statistically different from those measured with the S459F and S461P Pol ε cancer mutants previously ([@bib87]; [@bib88]), suggesting a common mechanism of mutagenesis for these hotspot mutations.

Mutation rates calculated using reporter genes (μ~L~) can be used to extrapolate to genome-wide per base pair mutation rates (μ~BS~) ([@bib21]; [@bib61]). The availability of high-throughput DNA sequencing now allows for empirical validation of these calculations in addition to providing insight into the influence of genomic context on mutagenesis. To address this we performed whole-genome sequencing (2.8 × 10^9^ bp at an average depth of 36.1x) on genomic DNA prepared from Pol ε^wt/exo-^ cells. Based on our measured mutation rate for HPRT1 (μ~L~) in Pol ε^wt/exo-^ cells lacking mismatch repair (180 × 10^−7^), we calculated a μ~BS~ value of 0.23 × 10^−7^ mutations per base pair per genome duplication.

Because the parental HCT-116 cell line already carries a significant number of single nucleotide variants (SNVs) relative to the human reference sequence (\[[@bib1]\] and see Discussion), we needed a way of measuring de novo mutations resulting from Pol ε-dependent replication errors. To do this we first performed whole genome sequencing (WGS) on genomic DNA prepared from mismatch repair-deficient Pol ε^wt/exo-^ cells, which we then used as a matched normal control. We termed this mutation spectrum P0. We then passaged these cells through a calculated 13.9 population doublings and then performed WGS again on the passaged population, which we termed P14. Mutations unique to P14 arose during the defined number of population doublings. The P0 and P14 samples contained 140.3 and 141.4 Mut/Mb, respectively. Given the calculated μ~BS~ and the 2.8 × 10^9^ bp sequenced, we predicted the accumulation of 906 novel genome-wide mutations after 14 population doublings. Whole-genome sequencing revealed 5,282 SNVs unique to the P14 population, 5.8-fold higher than that predicted from the μ~L~ at HPRT1. Mutations observed in HPRT1 in this cell line may thus slightly underrepresent those found genome-wide. This difference is consistent with what is seen in microbes, where reporter gene mutation rates are consistently 6--8-fold lower than concurrently measured whole-genome mutation rates, likely due to phenotypic lag, strong selective pressure and transcription in the reporter gene ([@bib22]; [@bib44]; [@bib53]).

C→A transversions exceeding 20% of all base pair substitutions is a primary characteristic of mutation spectra from tumors containing Pol ε exonuclease domain mutations ([@bib79]; [@bib87]). C→A transversions were increased significantly in the Pol ε^wt/exo-^ cells as compared to the control Pol ε^wt/wt^ spectrum, accounting for 46% of all base pair substitutions ([Figure 2A](#fig2){ref-type="fig"}, χ^2^ = 11.874, p\<0.0001). These were not cell line artifacts, as whole exome sequencing from HCT-116 cells from two independent studies (\[[@bib1]\] and this study) showed roughly 10% C→A transversions ([Figure 2A](#fig2){ref-type="fig"}, p\>0.5). HCC2998 cells, which harbor the Pol ε^wt/P286R^ mutation, also showed a significant increase in C→A transversions relative to Pol ε^wt/wt^ cells ([Figure 2A](#fig2){ref-type="fig"}, p\<0.0001).

![Whole-genome sequencing from defined population doubling Pol ε^wt/exo-^ mismatch repair-deficient cells.\
(**A**) Whole genome sequencing (2.8 × 10^9^ bp, average 30X coverage) was performed on Pol ε^wt/exo-^ cells lacking mismatch repair at two defined population doubling levels, P0 and P14, as described in the Methods. P0 was used as the matched normal cells to define only those mutations arising during the 14 population doublings. The fraction of each type of base pair substitution from the PD 14 Pol ε^wt/exo-^ cells was plotted and compared to the fraction of each type of mutation from HCT116 (([@bib1]) and this study) and HCC2998 cells ([@bib1]). Chi square tests with Yates correction were used to calculate p values relative to SNVs found in Pol ε^wt/wt^ mismatch repair-deficient cells in this study. Pol ε^wt/wt^ (Abaan et al.) χ^2^ = 0.033, p=0.8551; Pol ε^wt/P286R^ (Abaan et al.) χ^2^ = 872.341, p\<0.0001; Pol ε^wt/exo-^χ^2^ = 2,3680.508, p\<0.0001. \*\*\*\*p\<0.0001; n.s., not significant. (**B**) The number of each indicated base pair substitution in a specific trinucleotide context was plotted from the PD 14 Pol ε^wt/exo-^ mismatch repair-deficient cells. The base pair substitutions shown (C \> A and T \> G transversions, left; C \> T transitions, right) are those found enriched in POLE tumors. Chi square tests with Yates correction were used to calculate p-values relative to SNVs found in Pol ε^wt/wt^ mismatch repair-deficient cells in this study. C \> A TCT χ^2^ = 152.772, p\<0.0001; T \> G TTT χ^2^ = 72.254, p\<0.0001. \*\*\*\*p\<0.0001.](elife-32692-fig2){#fig2}

Two sequence context mutational hotspots were observed that are consistent with Pol ε exonuclease domain mutant spectra: C→A transversions in TCT context and T→G transversions in TTT context and, to a lesser extent, ATT and GTT contexts ([Figure 2B](#fig2){ref-type="fig"}). These hotspots are seen in Pol ε tumors from patients with bMMRD ([@bib88]), colorectal and endometrial cancer ([@bib7]; [@bib16]; [@bib46]; [@bib87]), as well as in the Pol ε-P286R HCC2998 cells ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, data extracted from \[[@bib1]\]). These are not mutational hotspots in HCT-116 cells, which contain wild type Pol ε ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). The largest number of mutations that arose during the 14 doublings were C→A transversions in triplet contexts containing adjacent cytosines: CCA, CCT, CCC and CCG. Triplet nucleotide occurrences can vary in the regions captured by WGS and WES. In order to address this we reanalyzed each sample relative to the number of times each trinucleotide is found in the relevant sample and found the hotspot patterns are all retained ([Figure 2---figure supplements 3](#fig2s3){ref-type="fig"}--[4](#fig2s4){ref-type="fig"}). The increase in C→A mutations in the CCT context was also seen in Pol ε exonuclease domain (EDM) tumors from bMMRD patients ([@bib88]), suggesting a link between Pol ε replication errors left uncorrected by mismatch repair. C→A mutations in CCA, CCC and CCG contexts are slightly elevated in Mutation Signature 20, which has been associated with loss of mismatch repair ([@bib6]). These transversions were seen in the HCT116 cell line with wild type Pol ε ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), though to a lesser extent. The lack of C→T transitions in TCG contexts is significantly different from colorectal and endometrial Pol ε tumors, but consistent with their absence from bMMRD tumors with Pol ε EDM mutations ([@bib16]; [@bib46]; [@bib87]).

Expression of MMR suppresses Pol ε^wt/exo-^ mutagenesis {#s2-2}
-------------------------------------------------------

While it is clear that Pol ε-dependent mutagenesis in the absence of functional MMR accounts for the ultramutated phenotype in bMMRD tumors with Pol ε mutations, the role of MMR in Pol ε somatic tumors is less clear. In order to measure the effects of MMR on Pol ε exonuclease-dependent replication errors, we wanted to measure error rates in both the presence and absence of MMR. Previous studies have restored MMR by stably adding Mlh1-expressing chromosome 3 to cells ([@bib28]). We made Mlh1-encoding lentivirus and used this to infect Mlh1-deficient HCT-116 cells containing wild type and mutant Pol ε ([Figure 3A](#fig3){ref-type="fig"}). Lentiviral Mlh1 expression reduced mutation rates at the HPRT1 locus by 14- to 20-fold in the wild type polymerase background ([Figure 3B](#fig3){ref-type="fig"}), similar to the 12-fold reduction reported when the Mlh1-encoding chromosome 3 was added back to HCT-116 cells (\[[@bib28]; [@bib92]\]; 73 × 10^−7^ and 5.9 × 10^−7^; 12.4-fold reduction), indicating that the expressed Mlh1 is functional.

![Mismatch repair suppresses exonuclease-deficient Pol ε-induced mutation rate increase.\
(**A**) Lentivirus encoding human Mlh1 was generated and used to infect parental cells with wild type Pol ε and cells heterozygous for Pol ε exonuclease deficiency. Cell lysates were probed by Western blot using antibodies against Mlh1 and β-actin. (**B**) Mutation rates were measured by fluctuation analysis as described in the Methods using the Ma-Sandri-Sarkar Maximum Likelihood Estimator. Twelve independent isolates from each of two parental (wt/wt) and two heterozygous cell lines (wt/exo-) expressing Mlh1 were used. 95% confidence intervals are shown. Pol ε^wt/wt^ Mlh1+ Clone 1 Mutation Rate = 1.7 × 10^−7^, SEM = 0.72 × 10^−7^, p=0. 0046. Pol ε^wt/wt^ Mlh1+ Clone 2 Mutation Rate = 2.5 × 10^−7^, SEM = 1.1 × 10^−7^, p=0.0053. Pol ε^wt/exo-^ Mlh1+ Clone 1 Mutation Rate = 2.3 × 10^−7^, SEM = 0.81 × 10^−7^, p\<0.0001 (vs. Pol ε^wt/exo-^ Mlh1- Clone 1) and p=0.0003 (vs. Pol ε^wt/exo-^ Mlh1- Clone 2). Pol ε^wt/exo-^ Mlh1+ Clone 2 Mutation Rate = 3 × 10^−7^, SEM = 1.3 × 10^−7^, p\<0.0001 (vs. Pol ε^wt/exo-^ Mlh1- Clone 1) and p=0.0003 (vs. Pol ε^wt/exo-^ Mlh1- Clone 2). Mutation Rates for Pol ε^wt/exo-^ Mlh1+ Clone 1 and Clone 2 were not significantly different (p=0.6485). Mutation rates from cells lacking mismatch repair (from [Figure 1A](#fig1){ref-type="fig"}) are shown for comparison.](elife-32692-fig3){#fig3}

Mlh1 expression in Pol ε^wt/exo-^ cells caused an over 50-fold decrease in the mutation rate (to 2.3 and 3.0 × 10^−7^, [Figure 3B](#fig3){ref-type="fig"}), making them indistinguishable from those measured in Pol ε^wt/wt^ cells with Mlh1 expressed ([Figure 3B](#fig3){ref-type="fig"}). This result also suggests that Msh3 is unlikely to play a significant role in correcting the exonuclease-deficient Pol ε errors since HCT-116 cells are deficient in this factor and it was not added back in these experiments ([@bib74]).

When fluctuation assay mutation rates are very low due to a significant number of independent isolates giving rise to zero HPRT1-mutant colonies, as was the case here, an alternative method to measure mutation rates can be used. We chose to periodically measure HPRT1 mutant frequencies at increasing population doubling level (PDL), where the slope of the plotted line is equal to the mutation rate ([@bib28]). We measured HPRT1 mutant frequencies at several population doublings from PDL = 0 to PDL = 70 or 71 in Pol ε^wt/wt^ and Pol ε^wt/exo-^ cells expressing Mlh1, respectively ([Figure 4A](#fig4){ref-type="fig"}). At each PDL we scored between 1 and 19 6-TG-resistant colonies. However, when we sequenced the HPRT1 ORF from all 6-TG-resistant colonies we saw many instances of repeat mutations in a collection from a single PDL, indicative of a single mutational event that expanded throughout the population. Plotting mutant frequency values calculated for the indicated PDL using only the unique HPRT1 mutations ([Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}) returned a line with slope of \~1, suggesting that the mutation rates were at or near the level of detection of this assay. The Pol ε^wt/exo-^ mutant frequencies were consistently higher than those from the Pol ε^wt/wt^ cells, but this difference was not statistically significant ([Figure 4A](#fig4){ref-type="fig"}).

![Mismatch repair suppresses the majority of exonuclease-deficient Pol ε mutation specificity.\
(**A**) Cells were continuously passaged and PDL was calculated using the following equation: PDL = \[ln(N~t~)-ln(N~0~\*PE)\]/ln2. N~t~ = Number of viable cells counted after passage; N~0~ = Number of cells seeded prior to passage; PE = plating efficiency. Mutant frequencies were measured for each mismatch repair proficient strain at the indicated PDL (diamonds, Pol ε^wt/wt^; triangles, Pol ε^wt/exo-^). Ten plates for each cell lines were seeded with 2 × 10^5^ cells at each PDL into media containing 6-TG and grown for 12--14 days. Each 6^TG^-resistant clone was isolated, expanded and the HPRT1 ORF was sequenced. Mutant frequencies were calculated based on the number of unique HPRT1 mutations at each PDL. Pol ε^wt/wt^ PDL6.4 MF = 1.8 × 10^−6^, SEM = 2.7 × 10^−6^, n = 4; Pol ε^wt/exo-^ PDL6.6 MF = 4.1 × 10^−6^, SEM = 3.1 × 10^−6^, n = 3, p=0.6003. Pol ε^wt/wt^ PDL44.6 MF = 1.1 × 10^−6^, SEM = 2.3 × 10^−6^, n = 2; Pol ε^wt/exo-^ PDL47.9 MF = 3.2 × 10^−6^, SEM = 4.7 × 10^−6^, n = 8, p=0.9066. Pol ε^wt/wt^ PDL69 MF = 1.5 × 10^−6^, SEM = 1.6 × 10^−6^, n = 5; Pol ε^wt/exo-^ PDL71 MF = 3.7 × 10^−6^, SEM = 2.6 × 10^−6^, n = 5, p=0.4917. (**B**) Whole exome sequencing (30 × 10^6^ bp, average 101x coverage) was performed on the indicated cell line at two defined population doubling levels, P0 and P69 or P71, as described in the Methods. P0 for each cell line was used as the matched normal cells to define only those mutations arising during the 70 or 71 population doublings. The fraction of each type of base pair substitution found unique to PDL 69 (for Pol ε^wt/wt^) or PDL 71 (Pol ε^wt/exo-^) was plotted and compared. Fisher's exact tests were used to calculate p values. p=0.0002 (\*\*\*p\<0.001).\
10.7554/eLife.32692.023Figure 4---source data 1.HPRT1 mutations sequenced from mismatch repair-proficient cells.The HPRT1 ORF was sequenced from individual HPRT1-resistant clones at the indicated PDL as described ([Figure 4A](#fig4){ref-type="fig"} and Materials and methods). One clone was unable to be sequenced (n.d.).\
10.7554/eLife.32692.024Figure 4---source data 2.Pol ε mutation spectra calculation of cosine similarity to cancer mutation spectra.Cosine similarities were calculated between the six unique mutation signatures extracted from POLE tumors and Pol ε mutant cell lines (columns, from [Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}) and each of the 30 identified Cosmic mutation signatures (<http://cancer.sanger.ac.uk/cancergenome/assets/signatures_probabilities.txt>).](elife-32692-fig4){#fig4}

To determine if this phenomenon held throughout the genome, we carried out whole-exome sequencing to an average depth of 100x on the early (PDL = 0) and late (PDL = 70) samples from both Pol ε^wt/wt^ and Pol ε^wt/exo-^ mismatch repair-proficient cell lines ([Figure 4B](#fig4){ref-type="fig"}). Using the PDL = 0 samples as matched normal controls, we measured similar low mutation rates in Pol ε^wt/wt^ and Pol ε^wt/exo-^ cells (13 × 10^−9^ Mut/bp/doubling and 18 × 10^−9^ Mut/bp/doubling, respectively). The total numbers of all mutations acquired were essentially no different than with wild type Pol ε. Interestingly, there was a statistically significant increase in C→A transversions (p=0.0002) between the mismatch repair-proficient Pol ε^wt/exo-^ cells and the mismatch repair-proficient Pol ε^wt/wt^ cells, while no statistically significant difference was found in any other class of base pair substitution (p\>0.2 for each of the six classes, Fisher's Exact Test). Further, all triplet context mutations were observed in insufficient numbers to evaluate statistically. C→A mutations were, however, observed in all triplet contexts seen as hotspots in the MMR-deficient cells (CCA, CCC, CCG, CCT and TCT, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Mutation signature 10, the unique Pol ε mutation signature, was extracted from Pol ε exonuclease-deficient mutation spectra from cells with and without mismatch repair ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"} and [Figure 4---source data 2](#fig4sdata2){ref-type="supplementary-material"}). The relative contribution of signature 10 in Pol ε exo-deficient cells is closer to that seen in bMMRD patients ([Figure 2---figure supplement 5](#fig2s5){ref-type="fig"}), most likely due to the relative absence of C→T transitions in TCG context. These results indicate that the majority of replication errors made by the Pol ε-D275A/E277A mutant are in fact corrected by mismatch repair.

Discussion {#s3}
==========

In the current study we examined the relative contributions of two essential determinants of replication fidelity, proofreading and mismatch repair, on mutagenesis in human cells. We used a combination of gene editing, reporter gene studies and next generation sequencing to measure mutation rates and specificities in human cells engineered to model proofreading-deficient tumors with and without mismatch repair. This is the equivalent to what occurs in human tumors with mutations in the Pol ε exonuclease domain and genomic mutation frequencies exceeding 100 mutations per Mb ([@bib16]; [@bib79]; [@bib87]; [@bib88]). We show that large and rapid mutation accumulation occurs when Pol ε exonuclease domain mutations occur along with inactivation of mismatch repair. Most of these are specific transversion mutations known to be hotspots of exonuclease-deficient Pol ε mutagenesis. We further show that this large increase in mutation rate is largely suppressed by functional mismatch repair. Taken together, these results suggest that the mechanism of replication error mutagenesis in sporadic tumors with heterozygous Pol ε mutations likely requires an additional feature, several of which are described below, including suppression of MMR and alternative effects on Pol ε activity.

We used rAAV-mediated gene targeting to replace two exonuclease active site residues, D275 and E277, with alanines on a single POLE allele. The single allelic inactivation was chosen to model the case in tumors with heterozygous Pol ε mutations. This double amino acid substitution has been shown to inactivate exonuclease proofreading in vitro and cause increased reporter gene mutation rates in yeast and mammalian cells ([@bib66]; [@bib68]; [@bib94]; [@bib4]; [@bib49]; [@bib85]; [@bib2]). Next generation sequencing on these cells in the presence or absence of mismatch repair over defined numbers of population doublings allowed us to compare genome-wide mutation rates and spectra to the mutation spectra from patient tumors.

Unbiased whole-genome sequencing confirmed the rapid accumulation of Pol ε-specific mutations seen in POLE tumors lacking functional mismatch repair ([@bib88]). The total number of measured SNVs suggests a mutation rate of 380 mutations per population doubling, similar to the 608 mutations per cell cycle calculated for a mismatch repair-deficient brain tumor harboring a Pol ε exonuclease domain mutation. Our cellular mutation rate values possibly underestimate the true Pol ε exonuclease-deficient mutation rate for several reasons. Our data were generated from a cancer cell line with a large number of pre-existing mutations ([@bib1]), as well as additional mutations that have assuredly arisen during passaging in the laboratory. These could conceivably include suppressor mutations functioning to restrain elevated mutation rates ([@bib68]; [@bib38]; [@bib98]). Importantly, no additional mutations in POLE were sequenced, suggesting that viability of this cell line is not due to an acquired mutation elsewhere in POLE acting to suppress the mutation rate, as occurs frequently in yeast ([@bib38]; [@bib98]; [@bib39]; [@bib20]). While we cannot formally exclude the possibility that a de novo mutation in another gene acted to suppress the mutation rate in trans, no obvious candidates were identified.

An additional reason that our mutation rates may underestimate the true mutation rate is that mutations that arise in the last several rounds of replication and those that fall below 5% allele frequency would not meet the threshold for scoring as a true SNV. The genome data was generated using an instrument with high accuracy (\<1% error rate) and variants were called using an established algorithm, however there are indeed a small number of areas in the genome that are inaccessible -- either due to gaps in the reference assembly, or excessive numbers of repeats that prevent proper alignment. Experiments using single-cell sequencing could address these issues, ideally by selecting single cells, expanding subclones and then measuring mutations at higher stringency values than used here. These rates are also similar to the per base pair mutation rates in haploid yeast with complete Pol ε exonuclease deficiency and disrupted MMR ([@bib48]). This similarity is striking considering our measurements were made in a heterozygous diploid human cell line. A key finding from the yeast study was that individual cell mutation rates could vary by an order of magnitude. We are currently unable to measure mutation rates in individual cells, but this remains a critical issue to address in future studies.

The unique mutation spectrum seen in POLE tumors was recapitulated in our gene-targeted cell lines, with one notable exception. In tumors, many C→A transversions occur in a highly specific triplet sequence context, TCT, which we also see in the cell lines, though not to the same proportion as in the tumor genomes. Interestingly, this particular mutation is also enriched in yeast with the P286R equivalent allele ([@bib9]). We also observe increased T→G transversions in TTT (and to a lesser extent ATT and CTT) context, similar to Pol ε tumors. Because of the limited number of mutational target sites we cannot at this time draw conclusions as to Pol ε strand usage during replication. Experiments designed to assess strand bias in these errors are currently underway. What is notable, however, is the lack of TCG→TTG transitions in our dataset. This is the second most frequent Pol ε-specific mutation in the TCGA database. TCG→TTG transitions were also not found elevated in the Pol ε bMMRD brain tumor mutation spectrum. This difference may reflect interesting, but as-yet undefined tissue differences.

Another possible explanation for these differences is that the Pol ε mutants found in tumors are somehow intrinsically different biochemically from the double alanine substitution mutant used in the current study. Depending on the reporter gene used, the monoallelic Pol ε-P286R mutant is a 2.3- to 12-fold stronger mutator than the pol2-4 mutant (equivalent to the human Pol ε D275A/E277A studied here) when measured in a diploid yeast strain ([@bib47]). However, a number of direct biochemical comparisons of activity and fidelity ([Figure 1C](#fig1){ref-type="fig"}, ([@bib87]; [@bib88]) and unpublished observations) between several cancer mutant constructs and the D275A/E277A construct have not yet shown any significant differences that could account for this. Certain DNA Pol mutants, including some found in human tumors, can cause increased mutagenesis by inducing expansions of normal dNTP pools in yeast and human cells ([@bib20]; [@bib63]; [@bib99]). Interestingly, the pol2-4 allele has no effect on dNTP pools in yeast, suggesting a possible explanation for possible allelic differences with functional MMR.

In heterozygous Pol ε^wt/exo-^ cells with functional mismatch repair, mutation rates were suppressed to the levels seen in cells with wild type Pol ε. These rates would be insufficient to give rise to ultrahypermutated tumors in a matter of months. In addition, there is no explosive accumulation of triplet context-specific mutations in the MMR-proficient Pol ε^wt/exo-^ cells that is seen in these tumors.

Given that the HCT-116 cells used in these studies are mutators themselves, it is possible that pre-existing deficiencies in other DNA repair or replication proteins could contribute to the observed mutagenesis. While direct contribution is unlikely given the absence of POLE mutation spectrum in the wild type Pol ε cells, cooperation with exonuclease-deficient Pol ε remains a formal possibility. To address this we used gene ontology to identify 58 DNA repair and replication proteins mutated in our HCT-116 cells, including 38 non-synonymous and 20 indel mutations. While several interesting candidates with known links to mutagenesis were identified, all have been shown by other groups to be expressed in this cell line and each, when tested, is functional (e.g. ATM, SETD2, Pol η, Pol ζ \[[@bib10]; [@bib31]; [@bib70]; [@bib103]; [@bib104]\]). No mutation that arose during the population doubling experiments showed any obvious link to mutagenesis.

Our results support a model in which simple heterozygous loss of two Pol ε exonuclease metal chelating residues on a single allele of POLE is insufficient to drive Pol ε ultramutational specificity. Additional factors are likely required to help drive the ultramutated phenotype observed in POLE tumors, including suppression of mismatch repair, discussed below. In bMMRD, the complete lack of mismatch repair prior to Pol ε mutation leads to the moderate accumulation of Pol ε-independent replication errors ([Figure 5](#fig5){ref-type="fig"}). Mutation rates then increase dramatically upon loss of proofreading in one allele, with the Pol ε error signature representing a smaller fraction of the total errors, which is seen in these tumors ([@bib88]). Our results suggest that Pol ε mutations in somatic tumors can occur first and early, but later suppression of MMR would then accelerate overall mutation rates to that seen in the ultramutated tumors, while the signature mutation proportion remains high ([@bib16]; [@bib46]).

![Model for Pol ε-dependent tumor mutation signature development.\
Rapid, massive mutation accumulation and Pol ε mutation signature acquisition (blue circles) depends on both Pol ε exonuclease domain mutation and compromised mismatch repair function. In somatic tumors, the partial MSI phenotype seen in a subset of POLE patients is likely the result of mismatch repair loss preceding Pol ε mutation (black line), leading to an accumulation of Pol ε-independent mutations (red circles). Mutations in bMMRD patients develop with similar mutation patterns, but accelerated timing due to germline loss of mismatch repair. When the Pol ε mutation occurs first during somatic tumor development, the mutation signature likely requires an additional characteristic for the explosive mutation acquisition to occur (blue line). Possibilities include subsequent suppression of mismatch repair (↓MMR?), unique biochemical properties (POLE^mut^?) or increased time and or cellular proliferation.](elife-32692-fig5){#fig5}

Analysis of the mutational status of all mismatch repair genes in Pol ε tumors sequenced by TCGA supports the model of mismatch repair loss dramatically accelerating the acquisition of Pol ε-specific mutations. 85% (22/26) of the TCGA Pol ε tumors also have a mutation in at least one mismatch repair gene, most of which (18/22) harbor at least one nonsense mutation, which are more likely to be inactivating mutations ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). This predicts that at least some tumors would show evidence of MSI. In the original TCGA studies, several POLE tumors were actually first classified as MSI (three as MSI-H; five as MSI-L) ([@bib16]; [@bib46]). Analysis of sequencing reads from 46 homonucleotide runs in the POLE endometrial tumors showed no evidence of instability, so the POLE tumors were then reclassified as MSS ([@bib87]). However, the initial TCGA studies used both homo- and di-nucleotide loci to score MSI, raising the possibility that a subset of POLE tumors have a microsatellite instability defect at repeats more complex than homonucleotides. Indeed, the repeat unit size, the number of repeats and the repeat sequence composition are known to have very strong influences on the variability of microsatellite mutagenesis ([@bib84]). Curiously, however, most (15/18) of the MMR gene nonsense mutations are the result of TCT→TAT transversions, raising the possibility that Pol ε mutation occurs first and possibly even promotes subsequent mutational inactivation of MMR.

Of all the Pol ε mutant colorectal and endometrial tumors sequenced in the TCGA studies, 15% (4/26) lacked a mutation in any mismatch repair gene and also showed no evidence of MLH1 promoter hypermethylation, demonstrating that the ultramutated phenotype can arise when mismatch repair is intact at both the genetic and epigenetic level. An alternative possibility is that mismatch repair activity is suppressed at some point during POLE tumor development. In this scenario, mutations introduced by the mutant Pol ε could accumulate slowly even in the presence of genotypically and epigenetically wild type mismatch repair. A number of conditions have been shown to transiently and reversibly lower mismatch repair protein levels and inhibit mismatch repair activity, including hypoxia, oxidative damage, inflammation, reduced pH, exposure to adriamycin or cadmium and treatment with mutagenic dNTP analogs ([@bib8]; [@bib26]; [@bib51]; [@bib64]; [@bib17]; [@bib40]; [@bib43]; [@bib57]; [@bib69]). The variable nature and duration of such a suppression event would be expected to result in a complex effect on microsatellite instability. Perhaps even more intriguingly, transient mismatch repair suppression has been seen in the context of proofreading-deficiency in E. coli ([@bib24]; [@bib83]). While replication errors made by the proofreading-deficient allele tested here were clearly insufficient to suppress MMR, it is possible that the nature and rate of errors made by cancer-associated alleles might be sufficient to saturate and overwhelm MMR pathways.

Our results support the idea that loss of a single Pol ε proofreading allele is sufficient to drive a subset of the observed clinical characteristics of Pol ε tumors, provided mismatch repair is compromised in some way. These observations further support the idea that in the presence of fully functional MMR the appearance of the ultrahypermutated mutation signature may be more directly related to some as yet uncharacterized additional defect in the mutant polymerase ([@bib9]). These ideas are not mutually exclusive of one another.

Given the recent success of immune checkpoint therapies in treating tumors with high mutation burden ([@bib88]; [@bib13]; [@bib41]; [@bib52]; [@bib82]), it is of great interest to understand the mechanisms that result in ultrahypermutated tumors harboring DNA polymerase mutations.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\   Designation                    Source or reference                           Identifiers                                                   Additional information
  or resource                                                                                                                                                          
  ------------------------- ------------------------------ --------------------------------------------- ------------------------------------------------------------- ----------------------------------------
  cell line (Homo\          HCT116 cells                   Other                                         RRID:[CVCL_0291](https://scicrunch.org/resolver/CVCL_0291)    Prescott Deininger at Tulane\
  sapiens, Male)                                                                                                                                                       Univeristy LCRC

  cell line\                HCT116 + Mlh1                  This paper                                    NA                                                            HCT116 cells stably expressing\
  (H. sapiens, Male)                                                                                                                                                   human Mlh1-ORF via\
                                                                                                                                                                       lentivirus-mediated integration

  cell line\                Exo-; Exonuclease-deficient\   This paper                                    NA                                                            HCT116 cells infected with rAAV\
  (H. sapiens, Male)        HCT116 Cells                                                                                                                               containing D275A and\
                                                                                                                                                                       E277A POLE mutations

  cell line\                Exo-; Exonuclease-deficient\   This paper                                    NA                                                            HCT116 cells stably expressing\
  (H. sapiens, Male)        HCT116 Cells + Mlh1                                                                                                                        human Mlh1-ORF via lentivirus-\
                                                                                                                                                                       mediated integration and infected\
                                                                                                                                                                       with rAAV containing D275A and\
                                                                                                                                                                       E277A POLE mutations

  recombinant\              ExoI-targeting rAAV vector     This paper                                    NA                                                            Homology arms/SEPT\
  DNA reagent                                                                                                                                                          Cassette/Exo- mutations

  recombinant\              pCMV-XL5-Mlh1                  Other                                         NA                                                            Victoria Belancio at\
  DNA reagent                                                                                                                                                          Tulane Univeristy LCRC

  antibody                  Mlh1 Antibody                  Pharmingen                                    G168-728;\                                                    Rabbit monoclonal; (1:100) in Milk\
                                                                                                         RRID: [AB_395227](https://scicrunch.org/resolver/AB_395227)   (1%) TBST (1X) x 1 hr at RT

  chemical compound, drug   6-Thioguanine; 6-TG            Sigma-Aldrich                                 A4882                                                         Used at 5 ug/mL final concentration

  chemical compound, drug   Hypoxanthine-Aminopterin-\     Thermo Fisher Scientific                      21060017                                                      Used at 1X final concentration
                            Thymidine; HAT                                                                                                                             

  chemical compound, drug   Geneticin; G418                Thermo Fisher Scientific                      10131027                                                      Used at 400 ug/mL\
                                                                                                                                                                       final concentration

  other                     Ad-CMV-Cre                     Vector Biolabs                                1045                                                          Adenovirus expressing Cre\
                                                                                                                                                                       recombinase for excision of SEPT\
                                                                                                                                                                       cassette from ExoI-targeted cell lines

  software, algorithm       BWA-MEM v0.7.8                 PMID: 19451168                                NA                                                            Used to align reads to\
                                                                                                                                                                       human reference

  software, algorithm       Picard v1.108                  Broad Institute;\                             NA                                                            Identify duplicate reads
                                                           <https://broadinstitute.github.io/picard/.>                                                                 

  software, algorithm       The Genome Analysis\           PMCID: PMC2928508                             NA                                                            locally realign reads to\
                            Toolkit (GATK) v2.8.1                                                                                                                      known indels and recalibrate\
                                                                                                                                                                       base quality scores

  software, algorithm       MuTect v1.1.4                  PMCID: PMC3833702                             NA                                                            Identiy somatic point mutations\
                                                                                                                                                                       between the tumour\
                                                                                                                                                                       and matched normal

  other                     WES/WGS raw\                   This paper                                    NCBI GEO\                                                     Raw FASTQ files for WES and\
                            sequencing data                                                              Accession:\                                                   WGS performed in this study
                                                                                                         PRJNA327240                                                   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Materials {#s4-1}
---------

Trypsin-EDTA was from Life Technologies and Geneticin was from Invitrogen. Antibodies against Mlh1 (mouse α-human Mlh1, G168-728) and β-actin (mouse α-human beta-actin, A1978) were from Pharmingen and Sigma, respectively.

Cell culture {#s4-2}
------------

The human colorectal cancer cell line HCT-116 (a kind gift from Dr. Prescott Deininger) was grown in HyClone MEM/EBSS (Thermo Scientific) supplemented with 10% fetal bovine serum (Atlanta Biologicals), 1% sodium pyruvate (Invitrogen) and 1% MEM-NEAA (Invitrogen). The HCT-116 cells used in this study were validated via analysis of genome-wide mutation signature, microsatellite instability and biomarker. HCT-116 cells lack Mlh1 resulting in a well-characterized MSI phenotype ([@bib60]; [@bib75]; [@bib12]). They further have a unique mutational spectrum that can be evaluated via next-generation sequencing ([@bib1]). Western blot analyses ([Figure 3A](#fig3){ref-type="fig"}) showed a lack of Mlh1 protein. The mutation spectrum from our whole-exome sequencing of HCT-116 cells ([Figure 2A](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}) is identical with that reported by Abaan ([@bib1]). Lastly, we performed microsatellite stability analysis in our HCT116 cells at five mononucleotide homopolymeric run loci (NR27, NR21, NR24, BAT25, BAT26) using capillary electrophoresis, which showed instability at these loci providing a phenotypic readout consistent with the lack of Mlh1 expression in our cells (data not shown). The HCT-116 cell line is also not in the 488 commonly misidentified cell lines from the most recent ICLAS database (Version 8.0) and tested negative for mycoplasma.

Generation of targeting constructs {#s4-3}
----------------------------------

In order to target the proofreading inactivating mutations to the POLE locus in vivo, we used rAAV with a synthetic exon promoter trap ([@bib78]). A 1045 bp fragment containing POLE exons 7 and 8 along with intron 7 (termed HA1) was PCR amplified from HCT-116 genomic DNA using primers designed to add unique NotI and SacI sites to the 5**\'** and 3**\'** ends, respectively. A 1057 bp fragment containing exons 9, 10 and 11 along with introns 9 and 10 (termed HA2) was PCR amplified from HCT-116 genomic DNA using primers designed to add unique EcoRI and NotI sites to the 5**\'** and 3**\'** ends, respectively. Both HA1 and HA2 were first cloned into pCR-TOPO and sequence verified. The catalytic exonuclease DIE residues located in HA2 (exon 9) were changed to AIA using site-directed mutagenesis and sequence verified. The Pol ε rAAV shuttle vector was assembled by four-way ligation using the restriction enzyme-digested gene-specific HA1 and HA2 fragments, along with the SEPT/loxP cassette digested with NotI-EcoRI and the ITR-containing pAAV shuttle vector digested with NotI (SEPT/loxP cassette and pAAV shuttle vectors were kind gifts of Dr. Fred Bunz, Johns Hopkins University). The Exo-targeting vector was used to package high-titer (1.6 × 10^6^ PFU/ml) recombinant adeno-associated virus into AAV2 serotype capsids.

Gene targeting and isolation of recombinant cell lines {#s4-4}
------------------------------------------------------

Cells were grown in 100 mm dishes and infected with rAAV when \~75--80% confluent. At the time of infection, cells were washed with 1x Hanks buffered saline solution (Invitrogen) before adding 3 ml of media containing 75 μl of a 1:250 dilution of rAAV lysate. 3 hr after infection an additional 6 ml of media was added to plates and allowed to incubate at 37°C for 48 hr. After 48 hr, media was changed and Geneticin was added to a final concentration of 400 μg/ml. Plates were then incubated under selection for an additional 14 days. At the end of the selection period, colonies from plates were isolated using glass cloning rings and 0.05% trypsin (Invitrogen) was used to transfer colonies to 6-well plates for subsequent expansion. Genomic DNA was extracted from expanded clones using DNeasy Blood and Tissue kit (QIAgen) according to the manufacturer's protocol and eluted in 100 μl of elution buffer. Locus-specific integration was assessed by PCR using a primer that annealed outside the homology region and another that annealed within the *neo* cassette.

Cre-mediated excision {#s4-5}
---------------------

To remove the SEPT cassette from correctly targeted clones, cells were infected in a 25 cm^2^ flask with adenovirus that expresses the Cre recombinase (1.0 × 10^6^ PFU/ml, Vector Biolabs, Philadelphia, PA). Cells were plated at a limiting dilution in nonselective medium 24 hr after infection. 12 days after infection, single cell colonies were plated in duplicate and geneticin was added to one set of wells at a final concentration of 400 μg/ml to test for sensitivity. During this time, genomic DNA was extracted as previously described and screened using primers that annealed across both homology arms. PCR products were digested with SacI to distinguish between the wild type and recombinant locus.

Southern blot analysis {#s4-6}
----------------------

Genomic DNA was harvested from the knock-in cell lines using the DNeasy Blood and Tissue Kit (Qiagen), and double digested with SacI and SalI. Hoechst fluorimetry was used to determine the concentration of DNA samples for accurate loading of samples. 4 μg of each sample was run on a 0.8% agarose gel in TBE. DNA was transferred to Hybond N + membrane (Amersham), blotted with a probe to HA2 at 65°C overnight, and washed at 65°C. To make the probe, a 300 bp sequence was amplified from the HA2-pCR-TOPO clone using the primers: 5ʹ-GCATCTGCCCCACTGTTAGT-3ʹ and 5ʹ-CTCCCTGTTGGTGATGAGGT-3ʹ. The PCR product was labeled using the Prime-It II Random Primer Labeling Kit (Agilent) and α-^32^P-dCTP (Perkin Elmer). Membrane was blocked in Denhardt's pre-hybridization buffer \[6x SSC, 0.5% SDS, 0.1% Ficoll 70, 0.1% Ficoll 400, 0.2% PVP, and 0.2%\] at 65°C for 1 hr. The probe was added to hybridization buffer \[6x SSC, 0.5% SDS, and 10% Dextran Sulfate\] and incubated overnight at 65°C. To wash off excess probe, the blot was washed for 2 × 15 min washes in wash 1 \[10x SSC, 0.5% SDS\], 2 × 15 min washes in wash 2 \[1x SSC, 1% SDS\], and 2 × 30 min washes in wash 3 \[0.1x SSC, 1% SDS\]. The gel was exposed to a PhosphorImage screen and scanned on a Typhoon Imager.

Purification of human Pol ε {#s4-7}
---------------------------

An expression vector encoding residues 1--1189 of the catalytic subunit of human Pol ε containing the D275A/E277A substitution was prepared as described ([@bib49]). Briefly, the human Pol ε was coexpressed in autoinduction medium with pRK603, which allows coexpression of TEV protease, at 25°C until the culture was saturated. Peak fractions from the HisTrap column were pooled, dialyzed into 50 mM HEPES, pH 7.5, 1 mM DTT, 5% glycerol and bound to SP sepharose. Bound protein was eluted with a 0--1 M with NaCl gradient. Peak fractions were pooled, dialyzed into 50 mM Tris, pH 7.5, 1 mM DTT, 5% glycerol, 100 mM NaCl and bound to Q Sepharose. Bound protein was eluted with a 100 mM--M M NaCl gradient. Peak fractions were pooled, concentrated and passed through a pre-equilibrated Superdex200 size exclusion column. Fractions containing the purified 140 kDa protein were pooled, dialyzed into 50 mM Tris, pH 8.0, 1 mM DTT, 5% glycerol and aliquots were frozen and stored at −80°C.

TCT→TAT in vitro error rate {#s4-8}
---------------------------

We previously reported that the lacZ forward mutation assay template lacks sites at which TCT→TAT transversions are phenotypically detectable ([@bib88]). To overcome this limitation we previously made a reversion substrate that reports only this mutation by using site-directed mutagenesis to change A~-11~ to C~-11~. Double-stranded M13mp2 DNA containing the TC~-11~T sequence was used as a substrate in reactions containing 0.15 nM DNA, 50 mM Tris-Cl, pH 7.4, 8 mM MgCl2, 2 mM DTT, 100 μg/ml BSA, 10% glycerol, 250 μM dNTPs and 1.5 nM Pol ε at 37°C. Completely filled product was transfected into Escherichia coli cells, which were used to determine the frequency of dark blue revertant plaques that occurred as a result of TCT→TAT transversions arising during DNA synthesis. In this assay, accurate DNA synthesis yields colorless plaques. Error rates were calculated according to the following equation: error rate (per nucleotide synthesized) = ((number of mutants of a particular class) × (mutant frequency)) / ((number of mutations sequenced) × (0.6) × (number of detectable sites)).

Mlh1 lentivirus construction {#s4-9}
----------------------------

Mlh1 ORF was PCR amplified using the pCMV-XL5-Mlh1 vector (kindly provided by Victoria Belancio, Tulane University), forward and reverse primers (fwd 5\'-TCGACTCGAGTCCACCATGTCGTTCGTGGCAGG-3\'; rev 5\'-TCGAGGATCCGTTACTTAACACCTCTCAAAGAC-3\') and Q5 DNA polymerase (NEB). After gel purification, dA was added to the 3\' ends with Taq and the Mlh1 ORF was cloned into pLenti6.3/V5-TOPO (Invitrogen). Mlh1 was found to have a common I219V SNP that does not affect Mlh1 function ([@bib77]). Mlh1 Lentiviral particles were made using the ViraPower Lentiral Expression System (Invitrogen). Briefly, 293FT cells were transfected with pLenti6.3/V5-TOPO-Mlh1 and a mixture of plasmids encoding lentiviral packaging factors. Viral supernatant was harvested 48 hr after transfection, filter sterilized and stored in aliquots at −80°C. After titering, HCT-116 cells were transduced with Mlh1 lentivirus at MOI of 1.0. Cells were selected for 1 week in 10 μg/ml blasticidin. Blasticidin-resistant clones were identified and cells were harvested, lysed and probed by Western blot (mouse α-human Mlh1, G168-728, Pharmingen) to confirm Mlh1 expression.

Mutation rate and mutant frequency measurements {#s4-10}
-----------------------------------------------

Prior to mutation rate measurements, preexisting HPRT1 mutants were eliminated from cell populations by incubating cells in HAT medium (1x Hypoxanthine-Aminopterin-Thymidine) for five passages. For each cell line analyzed, 500 cells were seeded and grown to confluence in 12 wells across two 6-well plates. Cells from one well were harvested and counted to estimate cell number in the remaining 11 wells. For mutation rate measurement, 500 cells from each of the remaining eleven wells were seeded per dish in 3 × 100 mm dishes in media lacking 6-TG to be used to measure plating efficiency. At the same time, 5 × 10^5^ cells from each of the remaining eleven wells were plated in 5 × 100 mm dishes in media containing 6-TG. After 7 days, colonies on the plating efficiency wells were stained with crystal violet and counted. After 12--14 days, the 6-TG resistant colonies were also stained with crystal violet and counted. Mutation rate was calculated using the Ma-Sandri-Sarkar Maximum Likelihood Estimator (MSS-MLE) method ([@bib81]).

For mutant frequency measurement, 500 cells per clone were seeded in duplicate in 6-well plates in media lacking 6-TG and allowed to grow for 5--7 days to determine plating efficiency. The remaining wells were seeded with 5 × 10^4^ cells in media containing 6-TG and allowed to grow for 12--14 days. After the indicated time, colonies were stained with crystal violet and counted. Mutant frequency was calculated by the following equation: (\# 6-TG resistant colonies) / (\[(\# colonies scored~PE~)/(\# cells seeded~PE~)\] x (\# cells seeded~6-TG~)). PE refers to plating efficiency. Colonies were defined as ≥50 cells.

HCT116 and HCT116 + Mlh1 cells were seeded into T75 flasks and grown at 37°C/5% CO~2~ until 80% confluency was reached. Cells were counted using the Countess Automated Cell Counter (Invitrogen) and 1 × 10^6^ cells were seeded into new T75 flasks and incubated until 80% confluency was reached. The above protocol was repeated at regular intervals (3--4 days) and population doubling (PDL) numbers calculated using the following equation: PDL = \[ln(N~t~)-ln(N~0~\*PE)\]/ln2. N~t~ = Number of viable cells counted after passage; N~0~ = Number of cells seeded prior to passage; PE = plating efficiency. At PDL \~ 6, 44 and 69 cells were trypsinized and counted. For mutant frequency measurement, 300 cells were seeded into each of 3 × 100 mm dishes in media lacking 6-TG to be used to measure plating efficiency. Concurrently, 2 × 10^5^ cells were seeded into each of 10 × 100 mm dishes in media supplemented with 6-TG to a final concentration of 5 μg/mL. After 7 days, colonies on the plating efficiency dishes were stained with crystal violet and counted. After 12--14 days, 6-TG resistant colonies were isolated using glass cloning rings and 0.05% trypsin and transferred into 24-well plates for expansion and RNA isolation. Additionally, at the above PDLs an aliquot of cells were harvested, lysed and probed by Western blot (mouse α-human Mlh1, G168-15, Abcam) to confirm maintenance of Mlh1 expression.

Genomic per base pair mutation rates (μ~BS~) were calculated using the method of Drake ([@bib21]) with modifications as applied in Lynch ([@bib61]). The equation used was: μ~BS~ = (μ~L~ • f~T~ • f~BS~) / (L • f~L~ • \[x (n~m~ + n~n~)/n~n~\]), where μ~L~ is the measured mutation rate at the HPRT1 reporter gene, f~T~ is the fraction of mutants found after sequencing, f~BS~ is the fraction of mutations due to base pair substitutions, L is the length (in nt) of the reporter gene, f~L~ is the fraction of HPRT1 that gives rise to detectable mutations, x is the fraction of mutations that would give rise to chain terminator mutations, n~m~ is the observed number of missense mutations and n~n~ is the observed number of nonsense mutations. We used 126 HPRT1 mutations from three independent studies ([@bib11]; [@bib28]; [@bib72]) to calculate μ~BS~. The values used were: f~T~ = 1.0, f~BS~ = 79/126 = 0.627; L = 627 nt; f~L~ = 1; x = 3/64 = 0.047; n~m~ = 74; n~n~ = 5. The μ~L~ value for Pol ε mutant cell lines was determined empirically using fluctuation analysis.

HPRT1 sequencing {#s4-11}
----------------

Total RNA was isolated using the Qiagen RNeasy kit (Qiagen) according to the manufacturer's protocol. RT-PCR was performed with SuperScript III Reverse Transcriptase (Invitrogen) according to the manufacturer's protocol using 1 μg of RNA as a template. Primer-specific cDNA was amplified for 32 cycles at an annealing temperature of 60°C using the following HPRT1 primers: 123(fwd) CTTCCTCCTCCTGAGCAGTC and 1041 (rev) GCCCAAAGGGAACTGATAGTC. From the HPRT1 sequencing of 6-TG resistant colonies, one clone was found to have exon 2 completely deleted. Exon deletions in HPRT1 have been shown to be caused by splice site mutations ([@bib11]). We therefore amplified exon 2 and its flanking region from genomic DNA prepared from the appropriate clone using the following primers: Forward: TTGTTTTCTTACATAATTCATTATCATACC; Reverse: TTACTTTGTTCTGGTCCCTACAGAG.

Whole genome and exome sequencing {#s4-12}
---------------------------------

Next generation sequencing was performed as per the published protocols. Whole genome sequencing (WGS) was performed on an Illumina HiSeq Xten instrument with libraries prepared using the manufacturer's TruSeq Nano DNA Library Prep kit and sequenced to a depth of 36.1x. For exome sequencing, DNA was enriched using Agilent SureSelect Human Exome Library Preparation V5 kit, then sequenced to a depth of 101.38x (96.61x-108.19x).

Substitution detection from next generation sequenced data {#s4-13}
----------------------------------------------------------

All samples were processed from raw reads (FASTQ files) from paired end libraries. The reads were aligned to the human reference (GRCh37 with decoy sequences) using BWA-MEM v0.7.8 ([@bib55]). Duplicate reads were identified and marked using Picard v1.108 (<https://broadinstitute.github.io/picard/>). The Genome Analysis Toolkit (GATK) v2.8.1 ([@bib62]) was used to locally realign reads to known indels and recalibrate base quality scores. Quality metrics were generated from the final BAM files to ensure high quality alignment. This includes:

-   average coverage \>90 x in whole exome data ([Figure 2---figure supplement 6](#fig2s6){ref-type="fig"} Mean_Coverage_Per_Sample.pdf)

-   alignment rate to the reference genome \>99% across whole exome data ([Figure 2---figure supplement 7](#fig2s7){ref-type="fig"} Proportion_of_properly_paired_reads.pdf) with \>60M reads per sample ([Figure 2---figure supplement 8](#fig2s8){ref-type="fig"} Total_Reads_Exome.pdf)

-   \>90% of bases in the genome at \>20 x coverage and \>90% of bases in the exome at \>30 x coverage ([Figure 2---figure supplement 9](#fig2s9){ref-type="fig"})

Limitations in the genome due to low-complexity regions and incomplete areas in the genome ([@bib56]) prevent proper alignment resulting in sources of error.

Somatic point mutations between the tumour and matched normal were identified using MuTect v1.1.4 ([@bib19]). In addition, we used MuTect v1.1.4 in single sample mode to detect all mutations in each sample. All mutations were annotated using ANNOVAR v20130823 ([@bib96]). Subsequent filtering was performed to reduce potential false positives and allow only high confidence mutations in the dataset using a custom R package (ShlienLab.Core.SNV v0.09). Mutations were retained if they met the following criteria:

-   not identified in common mutation databases including: dbSNP (138), 1000 genomes (1000g2012feb), complete genomics (CG69), Exome sequencing project (ESP 6500si)

-   for exome data, must have at least 20x normal and 30x tumour

-   for WGS data, must have at least 10x normal and 10x tumour ([Figure 2---figure supplement 10](#fig2s10){ref-type="fig"})

To investigate the quality of somatic mutations, we also identified key metrics including:

-   Average alternate base quality to reference base quality of \~1.0 ([Figure 2---figure supplement 11](#fig2s11){ref-type="fig"}, mean_ratio_tumour_alt_ref_base_quality.pdf)

Data access {#s4-14}
-----------

DNA sequencing data from this study have been submitted to the NCBI Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) under accession number PRJNA327240.
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The following dataset was generated:

Hodel KP2016Homo sapiens Raw sequence reads - BioProject<https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA327240>Publicly available at NCBI BioProject (Accession no. PRJNA327240)

The following previously published dataset was used:

Abaan OD2013NCI-60 mutation dataset<https://cancer.sanger.ac.uk/cosmic/download>Publicly available in the Catalogue Of Somatic Mutations In Cancer (COSMIC) database at the Wellcome Sanger Institute (file labelled: \'CosmicMutantExport.tsv.gz\')
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Explosive mutation accumulation triggered by human Pol ε proofreading-deficiency is driven by a complex mechanism\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors and the evaluation has been overseen by Sean Morrison as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This manuscript discusses the interrelationship between Pol epsilon proofreading deficiencies and defects in mismatch repair and their effects on mutational frequencies. Hodel et al. use human cell lines with different combinations of defects in proofreading and MMR and perform sequencing to compare their mutational spectra with that of tumors from patients with biallelic mismatch repair deficiency. The authors have chosen to study the D275A/E277A double substitution in human Pol epsilon, which has not been found in cancers, but is a well-characterized mutant in both yeast and mouse. Thus, it is a good choice for this type of study because it is catalytically dead and the results can be compared to observations in model organisms. It is already known that tumors with exonuclease deficient Pol epsilon and mismatch repair have a very high mutation load. However, the mutation rates cannot be measured in tumors, only the frequency. Here the authors determine the mutation rates in both wt/exo-deficient POLE cells with or without functional mismatch repair. The authors find that unaffected mismatch repair is able to entirely suppress mutation accumulation caused by deficiencies on proofreading, suggesting that additional defects are required to explain mutation acquisition in tumors containing proofreading-deficient Pol epsilon.

Essential revisions:

1\) This is a comprehensive study that provides insight into the mechanisms underlying mutation accumulation in a human cell line, with a direct relevance to clinically relevant cancers. The key issue that was raised during review of the manuscript is that the main outcomes of the work are poorly articulated in the context of the existing literature and the field\'s current understanding of the impact of proofreading deficiencies on mutation accumulation. In particular, the authors should better rationalise their study design using mono-allelic Pol epsilon exo minus and contrast it with previous work on model systems that were bi-allelic in proofreading deficiency. The way the manuscript currently reads, it is not clear why only one allele of Pol epsilon is inactivated. Relatedly, they should better articulate the relevance of their work to the clinical situation compared to previous work on model systems.

2\) Throughout the manuscript, several graphs and values do not contain error bars/margins. This is a significant concern, with the interpretation of the results critically relying on an understanding of the robustness of the experimental values.

3\) The authors suggest that Pol epsilon exo-minus tumors lacking all mismatch repair function are microsatellite stable. A complete lack of mismatch repair typically leads to microsatellite instability and as a result the microsatellite stable phenotype was seen as surprising by one of the reviewers. The authors should provide a rationalisation for this observation.

4\) The Title of the manuscript is misleading. The authors claim the mutation accumulation driven by a pol epsilon deficiency is \"complex\", yet the data presented is convincing that its driven by a mismatch repair deficiency.

10.7554/eLife.32692.034

Author response

> Essential revisions:
>
> 1\) This is a comprehensive study that provides insight into the mechanisms underlying mutation accumulation in a human cell line, with a direct relevance to clinically relevant cancers. The key issue that was raised during review of the manuscript is that the main outcomes of the work are poorly articulated in the context of the existing literature and the field\'s current understanding of the impact of proofreading deficiencies on mutation accumulation. In particular, the authors should better rationalise their study design using mono-allelic Pol epsilon exo minus and contrast it with previous work on model systems that were bi-allelic in proofreading deficiency. The way the manuscript currently reads, it is not clear why only one allele of Pol epsilon is inactivated. Relatedly, they should better articulate the relevance of their work to the clinical situation compared to previous work on model systems.

We thank the reviewers for their critical assessment of this manuscript. We chose to inactivate a single allele of Pol epsilon so as to be consistent with what is seen in Pol epsilon patient tumors as well as inherited germline mutations in Pol epsilon. In almost all reported cases of hypermutated POLE tumors, the Pol epsilon mutation is heterozygous with no reported loss of heterozygosity (LOH). Cell lines created from these tumors are also heterozygous for the Pol epsilon mutation. Since the wild type allele is presumed to be expressed in these tumors, important questions regarding full or partial dominance of the mutant allele remain unaddressed. Indeed, results from yeast suggest that the mutator phenotype arises in the diploid heterozygous mutant. Thus, constructing a mono-allelic system is critical to understanding the mutagenic and clinical situation in these patients. Our previous biochemical work demonstrated that the Pol epsilon mutant studied here is an appropriate model to study in cells. Specifically, the proofreading exonuclease activity defects of the current mutant are comparable to those of several patient-derived mutations studied. We regret that we did not make this more clear and have strengthened this rationale in the introduction.

POLE tumors are clinically characterized by several criteria, including being hypermutant, being heterozygous with no LOH, having a unique mutational signature and being microsatellite stable (MSS). (There is some discrepancy regarding this last criteria that we discuss in greater detail later in this response.) The current study in part aims to help better understand the mechanisms responsible for these clinical characteristics in the context of the rich history of work on Polymerase epsilon and δ mutants in model systems. Our results establish that loss of 3'-5' exonuclease activity in one allele is sufficient to drive several of these clinical criteria (the hypermutant phenotype and most of the unique mutational signature) when present in the heterozygous state, provided MMR is non-functional. These results are consistent with what is seen for mutation rates in Pole^wt/exo-^ MMR-deficient yeast and in the special case of bMMRD patients who develop spontaneous POLE heterozygous mutations in the complete absence of MMR. Perhaps most importantly, we believe that the lack of a hypermutant phenotype when MMR is fully restored in our Pole^wt/exo-^ monoallelic cell model helps explain the lack of tumors observed in the equivalent Pole^wt/exo-^ monoallelic mouse model system. We believe that functional MMR in these mice, Pole^wt/exo-^ and MMR-proficient, restrains the development of the unique hypermutant phenotype, thus preventing tumor development. These observations support the idea that the pathogenicity of POLE mutants may be more directly related to some additional defect in the mutant polymerase (Barbari and Shcherbakova, 2017). The best example of this is the much stronger effects on mutation rate in yeast for the P286R equivalent mutation than for the D275A/E275A mutant equivalent (Kane and Shcherbakova, 2014). This idea is further supported by studies in yeast on Pol δ mutants that showed differing effects on mutagenesis for engineered exo-domain mutants vs mutants selected for mutagenesis over generations (Murphy et al., 2006, Genome). Based on our work and those of model systems, we believe that a subset of the clinical criteria arise solely from loss of a single allele of polymerase proofreading, while the full set of clinical characteristics are dependent on the particular POLE allele. The mutations found in POLE tumors by definition satisfy all criteria. This idea can be tested directly in our cell model system by comparing patient-derived POLE mutations directly to the mutant used in the current studies. We have made every effort to better articulate these views and observations throughout the text.

> 2\) Throughout the manuscript, several graphs and values do not contain error bars/margins. This is a significant concern, with the interpretation of the results critically relying on an understanding of the robustness of the experimental values.

We thank the reviewers for this critical observation. We have now provided the relevant information where applicable:

[Figure 1A: p](#fig1){ref-type="fig"}-values have been added to the figure legend.

[Figure 1B](#fig1){ref-type="fig"}: Error bars have been added to the figure. We also now report the mean, SEM, n and exact p-value in the figure legend. BPS and FS error rate uncertainties were propagated using the following formula (ER, Error Rate): 𝜎~ER~ = ER \* sqrt((𝜎~Mutation\ Class\ Proportion~/Mutation Class Proportion)^2^+(𝜎~Mutation\ Rate~/Mutation Rate)^2^).

[Figure 1C](#fig1){ref-type="fig"}: We have removed [Figure 1C](#fig1){ref-type="fig"} from the manuscript as there are not enough data to draw statistically reliable conclusions concerning the TCT\>TAT Error Rate at the HPRT1 locus.

[Figure 1D](#fig1){ref-type="fig"} (which is now [Figure 1C](#fig1){ref-type="fig"} in the revised manuscript): We now compare enzymatic error rates for in vitro TCT\>TAT reversion using a Chi-squared analysis. This is consistent with the statistical methods we reported previously (Shlien et al., 2014). We also provide comparison to clinically relevant mutant Pol ε. p-values and the chi-square statistic are provided in the table.

[Figure 2A](#fig2){ref-type="fig"}: The data presented are proportions of counts observed for each BPS class in a single population and are thus treated as a single experiment and analyzed via chi-square analysis. We have amended the figure legend to contain the chi-square statistic and p-values.

[Figure 2B](#fig2){ref-type="fig"}: We have now indicated significance for the indicated Pol ε hot spot mutations and state the chi-square statistic and p-value in the figure legend.

[Figure 3B](#fig3){ref-type="fig"}: We now report the uncertainty values shown in the figure for the Mlh1-corrected clones in the legend in addition to the mean and p-values.

[Figure 4A](#fig4){ref-type="fig"}: Summary statistics are now made available in the figure legend.

[Figure 4B](#fig4){ref-type="fig"}: The p value was previously reported as p=0.0006. The actual value, p=0.0002, is now correctly reported.

> 3\) The authors suggest that Pol epsilon exo-minus tumors lacking all mismatch repair function are microsatellite stable. A complete lack of mismatch repair typically leads to microsatellite instability and as a result the microsatellite stable phenotype was seen as surprising by one of the reviewers. The authors should provide a rationalisation for this observation.

We did not mean to suggest that Pol epsilon exo-deficient tumors lacking all MMR function are microsatellite stable. It is clear from the literature that tumors initiating from a complete inactivation of MMR give rise to readily detectable MSI phenotype, which is generally MSI-H. Even in bMMRD patients with fully biallelic exonuclease-proficient Pol ε clearly show MSI in tumors. We apologize for not making this more clear. We have rewritten the discussion to more clearly reflect this and the following discussion. Rather, we are intrigued by the subset of POLE hypermutant tumors that were initially clinically diagnosed as MSI-L and MSI-H by PCR analyses and had mutations in various mismatch repair genes. Analysis of the WES/WGS data showed no evidence of instability in 46 homonucleotide runs (Shinbrot, 2013). We envision three testable possibilities to explain the discrepancy in the clinical data: (1) POLE-induced mutations arise independently of MMR; (2) MMR is saturated by excessive mutant POLE-induced replication errors; (3) MMR is transiently suppressed in POLE tumors for some unknown period of time.

In the first case, MMR would be fully functional throughout tumor progression. The discrepancy in MSS vs MSI-L/-H POLE clinical data could be explained by false positives in the initial data. Indeed, microsatellite marker sensitivity is sensitive to the specific sequence being examined. In fact, one of the most variable MSI markers in common use, the dinucleotide D5S346 marker \[Hile and Eckert, 2013\], was used in both of the large cohort next generation TCGA studies on colorectal and endometrial cancers \[TCGA, 2012 and Kandoth, 2013\]. This case is further supported by the re-analysis demonstrating stability in a panel of over 40 mononucleotide sequences by NGS \[Shinbrot, 2013\]. As no mutagenesis was observed using our exo-deficient mutant, an allele-specific mutagenesis would explain this case. Careful re-examination of more complex microsatellite sequences in the tumor data would help resolve this.

The second case would be consistent with studies in extreme mutators in model systems. However, the exonuclease-deficient mutant studied here clearly does not saturate functional mismatch repair in the cell model system. This further underscores the possibility that allele-specific differences in POLE mutants could be driving the observed mutagenesis. As discussed above, studies with the P286R mutant in yeast support this model and need to be corroborated in human cell models. These studies are ongoing in our laboratory.

The third case would suggest that MMR is functionally compromised for some period of time. This would be consistent with the original clinical diagnosis of MSI-L/-H for a subset of POLE tumors and could resemble a situation more resembling alternative-MSI. A-MSI occurs in certain cases of MSI-L caused by instability at more complex repeats; and in cases of EMAST, or Elevated Microsatellite Alterations at Selected Tetranucleotide repeats. These cases are generally not seen in tumors with complete MMR inactivation (e.g. MLH1 or MSH2 loss). They occur more frequently from loss of PMS2, MSH3, Pol kappa or even increased environmental DNA damage. This case would also be consistent with a number of reports in the literature showing that certain types of MMR suppression are reversible. These are generally via chemical treatments, including adriamycin, Cadmium, Zinc and a DNA base analog (Larson et al., 2000; Banerjee et al., 2005; Negishi et al., 2002). Appearance of a true MSI phenotype would be dependent on the nature and length of exposure, as well as the microsatellite sequence. One interesting set of experiments demonstrates the highly variable nature of observable MSI phenotype when MMR is transiently suppressed (Koole et al., 2013). Using a fluorescent reversion reporter and siRNA against MSH2, they showed that even the most sensitive reporter used (23 guanines) required two rounds of knockdown and two weeks of passaging before 4% of cells showed detectable MSI at the reporter. This would be below the detection level of all but the highest depth WES/WGS. Interestingly, in this system no MSI was detectable for adenine or thymine runs, or for runs less than 11nt. This is a very interesting area of future studies as patient exposures are highly variable over a lifetime.

> 4\) The title of the manuscript is misleading. The authors claim the mutation accumulation driven by a pol epsilon deficiency is \"complex\", yet the data presented is convincing that its driven by a mismatch repair deficiency.

While the data are convincing that mismatch repair deficiency is driving mutation accumulation with the exonuclease-deficient allele in the current study, our title was chosen to reflect the possibility raised by studies in yeast that the cancer mutants are somehow intrinsically different with respect to mutagenesis in vivo (Kane and Shcherbakova, 2014). This remains speculative in the absence of any functional data using human cells. We have revised our title to more accurately reflect the data as presented.
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